Plasma metabolomic profiling as a tool to identify predictive biomarkers of methotrexate efficacy in rheumatoid arthritis.

导出 OA

翻译打印收藏纠错

作者： Matthew R,Medcalf ^[1] ; Leonidas E,Bantis ^[2] ; Peng,Shi ^[2] ; Pooja,Bhadbhade ^[3] ; Rebekah L,Gundry ^[4] ; Ted R,Mikuls ^[5] ; Bryant R,England ^[5] ; James R,O'Dell ^[5] ; Ryan S,Funk ^[6]

作者单位： Department of Pharmacy Practice, University of Kansas, Kansas City, KS, United States. ^[1] Department of Biostatics & Data Science, University of Kansas Medical Center, Kansas City, KS, United States. ^[2] Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, United States. ^[3] Department of Cellular and Integrative Physiology, CardiOmics Program, Center for Heart and Vascular Research, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, United States. ^[4] Department of Internal Medicine, Division of Rheumatology & Immunology, University of Nebraska Medical Center (UNMC), Omaha, NE, United States; VA Nebraska-Western IA Health Care System, Omaha, NE, United States. ^[5] Department of Pharmacy Practice, University of Kansas, Kansas City, KS, United States. Electronic address: ryanfunk@kumc.edu. ^[6]

关键词 Biomarker Metabolome Metabolomics Methotrexate Plasma Rheumatoid arthritis

主题词抗风湿药(Antirheumatic Agents);关节炎, 类风湿(Arthritis, Rheumatoid);药物疗法, 联合(Drug Therapy, Combination);人类(Humans);甲氨蝶呤(Methotrexate);治疗结果(Treatment Outcome)

DOI 10.1016/j.semarthrit.2022.152056

PMID 35785666

发布时间 2023-10-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交